A statement released earlier today by equinet AG about Bayer (ETR:BAYN) bumps the target price to 118.00EUR
- Updated: September 15, 2016
Boasting a price of 91.44EUR, Bayer (ETR:BAYN) traded 0.00% even on the day. The last stock close is up 1.82% relative to the two hundred day average, compared to the S&P 500 which has fallen -0.01% over the same period. Bayer has logged a 50-day average of 0.04EUR and 200-day moving average of 0.03EUR. 0 shares of Bayer traded, down from ann avg. trading volume of 211
In a report announced on 9/16/2016 equinet AG raised the target price of Bayer (ETR:BAYN) from 0EUR to 118EUR indicating a possible upsideof 0.29%.
Previously on Monday August 29 2016, Citigroup Corp. reported about Bayer(ETR:BAYN) bumped the target price from 0.00EUR to 120.00EUR. At the time, this suggested an upside of 0.24%.
See Graphic Below:
Bayer has a one-year low of 0.03EUR and a 52 week high of 0.04EUR. The company’s market capitalization is currently 0.0 EUR.
General Company Details For Bayer (ETR:BAYN)
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, and adhesives and sealants; and selected chemical intermediates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.